

NICE Technology Appraisals (medicines): Formulary Adherence 2018/2019

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes	N/A	Date of local decision due (90 days)	Date of local decision made	Time to implement days
TA508 – Autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee	7 th March 2018	Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee.	Y		05/06/2018	18/04/2018	42
TA509 pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer	7 th March 2018	Evidence-based recommendations on pertuzumab for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before. NHSE Cancer Drug Fund	Y		05/06/2018	18/04/2018	42
TA510 – Daratumumab monotherapy for treating relapsed and refractory multiple myeloma	14 th March 2018	Evidence-based recommendations on Daratumumab for relapsed or refractory multiple myeloma in adults. NHSE Cancer Drug Fund	Y		12/06/2018	18/04/2018	35
TA511 – Brodalumab for treating moderate to severe plaque psoriasis	21 st March 2018	Evidence-based recommendations on brodalumab for treating moderate to severe plaque psoriasis in adults. CCG commissioned (Blue Teq Form)	Y		19/06/2018	18/04/2018	28
TA512 – Tivozanib for treating advanced renal cell carcinoma	21 st March 2018	Evidence-based recommendations on tivozanib for treating advanced renal cell carcinoma in adults. NHSE Commissioned	Y		29/06/2018	18/04/2018	28
TA513 – Obinutuzumab for untreated advanced follicular lymphoma	21 st March 2018	Evidence-based recommendations on obinutuzumab for untreated advanced follicular lymphoma in adults. NHSE Commissioned	Y		29/06/2018	18/04/2018	28
TA514 – Regorafenib for previously treated advanced hepatocellular carcinoma	21 st March 2018	Evidence-based recommendations on regorafenib for previously treated advanced hepatocellular carcinoma in adults. (Not recommended)		N/A	29/06/2018	18/04/2018	28
TA515 – Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen	28 th March 2018	Evidence-based recommendations on eribulin for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy. (Not recommended)		N/A	06/05/2018	18/04/2018	21
TA516 – Cabozantinib for treating medullary thyroid cancer	28 th March 2018	Evidence-based recommendations on cabozantinib for treating medullary thyroid cancer in adults. NHSE Cancer Drug Fund	Y		06/05/2018	18/04/2018	21
TA517 – Avelumab for treating metastatic Merkel cell carcinoma, only if they have had 1 or more lines of chemotherapy for metastatic disease.	11 th April 2018	Evidence-based recommendations on avelumab (Bavencio) for treating metastatic (secondary) Merkel cell carcinoma in adults. NHSE Cancer Drug Fund	Y		10/07/2018	16/05/2018	35
TA518 – Tocilizumab for treating giant cell arteritis.	18 th April 2018	Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults. NHSE Commissioned	Y		17/07/2018	16/05/2018	28
TA519 – Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	25 th April 2018	Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated locally advanced or metastatic urothelial carcinoma in adults. NHSE Cancer Drug Fund	Y		24/07/2018	16/05/2018	21
TA520 – Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy	16 th May 2018	Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults. NHSE Commissioned	Y		14/08/2018	20/06/2018	35
TA521 – Guselkumab for treating moderate to severe plaque psoriasis in adults	13 th June 2018	Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults. NHSE Commissioned	Y		11/09/2018	20/06/2018	7

NICE Technology Appraisals (medicines): Formulary Adherence 2018/2019

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

TA525 – Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy.	13 th June 2018	Evidence-based recommendations on Atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults. (there is a separate guidance for people with untreated disease who cannot have cisplatin-based chemotherapy) NHSE Commissioned	Y		11/09/2018	20/06/2018	7
TA522 – Pembrolizumab for untreated PD0L1 –positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	13 th June 2018	Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults. NHSE Cancer Drug Fund	Y		11/09/2018	18/07/2018	35
TA523 – Midostaurin for untreated acute myeloid leukaemia	13 th June 2018	Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults. NHSE Commissioned	Y		11/09/2018	18/07/2018	35
TA524 – Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma	13 th June 2018	Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults. This guidance is a Cancer Drugs Fund reconsideration of brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446). This guidance replaces TA446. NHSE Cancer Drug Fund	Y		11/09/2018	18/07/2018	35
TA526 – Arsenic trioxide for treating acute promyelocytic leukaemia	13 th June 2018	Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults. NHSE Commissioned	Y		11/09/2018	18/07/2018	35
TA527 – Beta interferons and glatiramer acetate for treating Multiple Sclerosis	27 th June 2018	Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults. NHSE Commissioned	Y		25/09/2018	18/07/2018	21
TA217 – Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	20 th June 2018 updated	Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults. CCG Commissioned	Y		18/09/2018	18/07/2018	28
TA528 – Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube peritoneal cancer	4 th July 2018	Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults. NHSE Cancer Drug Fund	Y		2/10/2018	19/09/2018	77
TA529 – Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer	4 th July 2018	Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults. NHSE Cancer Drug Fund	Y		2/10/2018	19/09/2018	77
TA530 – Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy	4 th July 2018	Evidence-based recommendations on nivolumab (Opdivo) for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy. (Not recommended)		N/A	2/10/2018	19/09/2018	77
TA531 – Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer	18 th July 2018	Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults. NHSE Commissioned	Y		16/10/2018	19/09/2018	63

NICE Technology Appraisals (medicines): Formulary Adherence 2018/2019

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes	N/A	Date of local decision due (90 days)	Date of local decision made	Time to implement days
TA532 – Cenegermin for treating neurotrophic keratitis	18 th July 2018	Evidence-based recommendations on cenegermin (Oxervate) for treating neurotrophic keratitis in adults. (Not recommended)		N/A	16/10/2018	19/09/2018	63
TA533 – Ocrelizumab for treating relapsing-remitting multiple sclerosis	18 th July 2018	Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing-remitting multiple sclerosis in adults. NHSE Commissioned	Y		16/10/2018	19/09/2018	63
TA522 – Pembrolizumab for untreated PD-L1 –positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	13 th June 2018 (updated 24 th July 2018)	Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults. July 2018: The European Medicines Agency restricted the use of pembrolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. NHSE Cancer Drug Fund	Y		22/10/2018	19/09/2018	57
TA492 – Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	6 th December 2018 (updated 12 th July 2018)	Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults. July 2018: The European Medicines Agency restricted the use of atezolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. NHSE Commissioned	Y		10/10/2018	19/09/2018	69
TA534 – Dupilumab for treating moderate to severe atopic dermatitis	1 st August 2018	Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults CCG commissioned (Blue Teq Form)	Y		30/10/2018	19/09/2018	49
TA535 – Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine	8 th August 2018	Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine. NHSE Commissioned	Y		6/11/2018	19/09/2018	42
TA536 – Alectinib for untreated ALK-positive advanced non-small-cell lung cancer	8 th August 2018	Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults. NHSE Commissioned	Y		6/11/2018	19/09/2018	42
TA537 – Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs	8 th August 2018	Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults. CCG commissioned	y		6/11/2018	19/09/2018	42
TA538 – Dinutuximab beta for treating neuroblastoma	22 nd August 2018	Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over. NHSE Commissioned	Y		20/11/2018	19/09/2018	28
TA539 – Lutetium oxodotreotide for treating unresectable or metastatic neuroendocrine tumours	29 th August 2018	Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults. NHSE Commissioned	Y		27/11/2018	19/09/2018	21
TA540 – Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma	3 rd September 2018	Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults. (not recommended in adults who have had autologous stem cell transplant & brentuximab vedotin)		N/A	3/12/2018	17/10/2018	45

NICE Technology Appraisals (medicines): Formulary Adherence 2018/2019

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes	N/A	Date of local decision due (90 days)	Date of local decision made	Time to implement days
TA540 – Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma	3 rd September 2018	Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had brentuximab vedotin and cannot have autologous stem cell transplant. Cancer Drugs Fund	Y		3/12/2018	17/10/2018	45
TA541- Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia	19 th September 2018	Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. NHSE Commissioned	Y		18/12/2018	17/10/2018	28
TA542 – Cabozantinib for untreated advanced renal cell carcinoma	3 rd October 2018	Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults. NHSE Commissioned	Y		01/01/2019	21/11/2018	49
TA543 – Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs	3 rd October 2018	Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs. CCG Commissioned – Blueteq form	Y		01/01/2019	21/11/2018	49
TA544 – Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma	17 th October 2018	Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults. NHS England Commissioned	Y		15/01/2019	21/11/2018	35
TA293 – Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura	24 th July 2013 Last updated 26 th October 2018	Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura in adults. This guidance updates and replaces NICE technology appraisal guidance on eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205). CCG Commissioned – Blueteq form	Y		25/01/2019	21/11/2018	26
TA221 – Romiplostin for the treatment of chronic immune (idiopathic) thrombocytopenic purpura	25 th April 2011 – Last updated 26 th October 2018	Evidence-based recommendations on romiplostin (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura in adults. CCG Commissioned – Blueteq form	Y		25/01/2019	21/11/2018	26
TA545 – Gemtuzumab ozogamicin for untreated acute myeloid leukaemia	14 th November 2018	Evidence-based recommendations on gemtuzumab ozogamicin (Mylotarg) for untreated acute myeloid leukaemia in people aged 15 years and over. NHS England Commissioned	Y		12/02/2019	19/12/2018	35
TA546 – Padeliporfin for untreated localised prostate cancer	21 st November 2018	Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults. (Not recommended)		N/A	19/02/2019	19/12/2018	28
TA547 – Tofacitinib for moderately to severely active ulcerative colitis	28 th November 2018	Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults. CCG Commissioned – Blueteq form	Y		26/02/2019	19/12/2018	21

NICE Technology Appraisals (medicines): Formulary Adherence 2018/2019

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes	N/A	Date of local decision due (90 days)	Date of local decision made	Time to implement days
TA548 Decitabine for untreated acute myeloid leukaemia	N/A-appraisal terminated	NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was received from Janssen.		N/A	N/A	N/A	N/A
TA549 – denosumab for preventing skeletal-related events in multiple myeloma	N/A-appraisal terminated	NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence submission was received from Amgen.		N/A	N/A	N/A	N/A
TA550 – Vandetanib medullary thyroid cancer	12 th December 2018	Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults. (Not recommended)		N/A	29/01/2019	16/01/2019	35
TA551 –Lenvatinib for untreated advanced hepatocellular carcinoma	19 th December 2018	Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma in adults. NHS England Commissioned	Y		05/02/2019	16/01/2019	28
TA552 – Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia	19 th December 2018	Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia in adults. Cancer Drugs Fund	Y		05/02/2019	16/01/2019	28
TA553 – Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence	19 th December 2018	Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of stage III melanoma with lymph node involvement in adults. Cancer Drugs Fund	Y		05/02/2019	16/01/2019	28
TA554 – Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years	21 st December 2018	Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. Cancer Drugs Fund	Y		07/01/2019	16/01/2018	26
TA555 – Regorafenib for previously treated advanced hepatocellular carcinoma	9 th January 2019	Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib. NHS England Commissioned	Y		05/03/2019	20/02/2019	42
TA556 – Darvadstrocel for treating complex perianal fistulas in Crohns disease	9 th January 2019	Evidence-based recommendations on darvadstrocel (Alofisel) for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease. (Not recommended)		N/A	05/03/2019	20/02/2019	42
TA557 – Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous, non-small-cell-lung cancer	10 th January 2019	Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. Cancer Drugs Fund	Y		06/03/2019	20/02/2019	41
TA558 – Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease	23 rd January 2019	Evidence-based recommendations on nivolumab (Opdivo) for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease. Cancer Drugs Fund	Y		19/03/2019	20/02/2019	28

NICE Technology Appraisals (medicines): Formulary Adherence 2018/2019

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes	N/A	Date of local decision due (90 days)	Date of local decision made	Time to implement days
TA559 – Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	23 rd January 2019	Evidence-based recommendations on axicabtagene ciloleucel therapy (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma in adults after 2 or more systemic therapies. Cancer Drugs Fund	Y		19/03/2019	20/02/2019	28
TA560 – Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first occurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)	20th February 2019	NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer because no evidence submission was received from Roche.	N/A	N/A	N/A	20/03/2019	N/A
TA561 – Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia	27 th February 2019	Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults. Cancer Drugs Fund	Y		28/05/2019	20/03/2019	21
TA562 – Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma	27 th February 2019	Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults. Cancer Drugs Fund	Y		28/05/2019	20/03/2019	21
TA563 – Abemaciclib with an aromatase inhibitor for previously untreated, hormone-receptor-positive, HER2-negative. Locally advanced metastatic breast cancer	27 th February 2019	Evidence-based recommendations on abemaciclib (Verzenio) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who have not had endocrine-based therapy before. Cancer Drugs Fund	Y		28/05/2019	20/03/2019	21
TA564 – Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)	27 th February 2019	NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer because no evidence submission was received from Novartis.	N/A	N/A	N/A	20/03/2019	N/A

Total	<u>51</u>	<u>12</u>			
	% "Yes"	% "No"			Average implementation time (days)
Adherence statistics for 2018 - 2019	<u>81</u>	<u>19</u>			35